NF1 protein structure

Brigitte Widemann leads early-phase trial that shows drug shrinks NF1 tumors

Brigitte Widemann, Chief of the Pediatric Oncology Branch, led an early-phase clinical trial testing the oral drug selumetinib on children with neurofibromatosis 1 (NF1) and plexiform neurofibromas. The trial results, published in the New England Journal of Medicine on Dec. 28, 2016, showed participants of this trial tolerated the drug and most responded with tumor shrinkage. “Some may say that a 20 percent volume reduction is too small to be meaningful, but to me, just stopping the growth of these devastating tumors is an important achievement,” Widemann says. “The difference we see in these patients is truly unprecedented.” Read more...

 

Brigitte Widemann leads early-phase trial that shows drug shrinks NF1 tumors

William Dahut Leads Discussion of Prostate Cancer Treatment Options

Posted: Jan 18, 2017

William Dahut, M.D., CCR Scientific Director for Clinical Research, was joined by Heather Cheng, M.D., of the University of Washington for a discussion about current and future research areas and treatment options for prostate cancer.  The panel was moderated by Ana Fadich, Vice President of the Men's Health Network. Learn more...

William Dahut Leads Discussion of Prostate Cancer Treatment Options

Dr. Alex Compton appointed as tenure track investigator

Posted: Jan 9, 2017

Alex Compton, Ph.D. has joined the HIV Dynamics and Replication Program (HIV DRP) as a tenure track Investigator.  Dr. Compton’s research is broadly focused on the antiviral innate immune response against HIV-1 infection. Learn more...

Dr. Alex Compton appointed as tenure track investigator

Christian Hinrichs discusses cancer research with PBS NewsHour’s Hari Sreenivasan

Posted: Jan 9, 2017

PBS NewsHour’s Hari Sreenivasan interviewed Christian Hinrichs, M.D., on Facebook Live to discuss cancer research and immunotherapy in Hinrichs’ lab. Hinrichs is an investigator who works in the Experimental Transplantation and Immunology Branch and researches immunotherapy for HPV cancers.  He says: “We’re very much on a mission here. It’s not a casual exploration. We’re trying to get better treatments and get them to the patients as quickly as possible. I think this is true of everybody in our lab. We get up and that’s what we’re trying to do is find a better treatment and get it to the patients. We’re trying to get more patients treated, and then the patients we’ve treated we’re trying to understand what’s going on with those patients so we can make better therapies.”

Christian Hinrichs discusses cancer research with PBS NewsHour’s Hari Sreenivasan

Novel Target for High-Risk Neuroblastoma Identified in Pre-Clinical Research

Posted: Jan 9, 2017

Pre-clinical research by investigators at the Center for Cancer Research and their colleagues have identified a number of novel epigenetic targets for high-risk neuroblastoma and validated a promising new targeted inhibitor in pre-clinical models.  Read more...

Novel Target for High-Risk Neuroblastoma Identified in Pre-Clinical Research

Molecules discovered that block cancer-associated microRNAs

Posted: Dec 29, 2016

Investigators from the Center for Cancer Research have identified a new class of compounds that block the action of a microRNA associated with the development of human cancers, cardiovascular diseases and immune disorders.  Read more...

Molecules discovered that block cancer-associated microRNAs

Dr. Frank Lin appointed as Lasker Clinical Research Scholar

Posted: Dec 28, 2016

Frank Lin, M.D. has joined the Molecular Imaging Program (MIP) as a Lasker Clinical Research Scholar.  Dr. Lin will perform pre-clinical and clinical research in the use of targeted radionuclide therapy (tRNT). Learn more...

Dr. Frank Lin appointed as Lasker Clinical Research Scholar

Potential treatment for radiation-induced lung injury identified

Posted: Dec 22, 2016

Researchers from the Center for Cancer Research’s Radiation Oncology Branch have identified a therapeutic target for the possible treatment of lung injury from radiation therapy. Read more...

Potential treatment for radiation-induced lung injury identified

A crucial step in cell division identified

Posted: Dec 20, 2016

When cell division doesn’t go according to plan, the resulting daughter cells can become unstable or even cancerous. A team of CCR investigators has now discovered a crucial step required for normal cell division to occur. Read more...

A crucial step in cell division identified

Chemotherapy drug shuts down cell growth by triggering a natural checkpoint

Posted: Dec 15, 2016

In a new study published November 23, 2016, in Molecular Cell, researchers in the CCR’s Laboratory of Cell and Developmental Signaling reported the discovery of a previously unknown route for blocking cell growth that can be activated by certain chemotherapy drugs to fight cancer. Read more...

Chemotherapy drug shuts down cell growth by triggering a natural checkpoint

Minimizing hazards associated with cancer vaccines

Posted: Dec 12, 2016

Sheri McMahon, Senior Research Nurse Specialist with the Genitourinary Malignancies Branch, published an article in the latest issue of the Clinical Journal of Oncology Nursing on minimizing hazards associatied with live-virus immunotherapeutic cancer vaccine injection sites. She says oncology nurses need to be familiar with how to manage patients' vaccine injection sites to minimize risks for patients and the community at large. Learn more...

 

Minimizing hazards associated with cancer vaccines

Pages